For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| General and administrative costs | 132,030 | 21,846 | 155,513 | |
| Total operating expenses | 132,030 | 21,846 | - | |
| Loss from operations | -132,030 | -21,846* | -155,513 | |
| Interest earned on cash and investments held in trust account | 4,439,850 | 4,411,961.25* | 109,355 | |
| Gain on extinguishment of over-allotment option liability | - | 138,437* | - | |
| Provision for credit losses | - | 203,028.25* | - | |
| Recovery of credit losses | -30,000 | - | - | |
| Total other income | 4,469,850 | 4,347,370* | 109,355 | |
| Net income (loss) | 4,337,820 | 4,325,524 | -46,158 | |
| Basic EPS | 0.07 | 0.181 | 0 | |
| Diluted EPS | 0.07 | 0.181 | 0 | |
| Basic Average Shares | 50,000,000 | 23,857,951 | 2,717,391 | |
| Diluted Average Shares | 50,000,000 | 23,857,951 | 2,717,391 | |
Drugs Made In America Acquisition II Corp. (DMII)
Drugs Made In America Acquisition II Corp. (DMII)